胰岛素样生长因子Ⅰ型受体及其单克隆抗体在肿瘤治疗中的研究进展

Research progress on insulin-like growth factor-Ⅰ receptor and its monoclonal antibody in tumor therapy

近年来，越来越多的研究表明胰岛素样生长因子Ⅰ型受体（insulin‐like growth factor‐Ⅰreceptor ，IGF‐ⅠR）在肿瘤的发生和发展中起重要作用，通过抑制IGF‐ⅠR信号通路可有效抑制多种肿瘤细胞在体内外增殖。此外，对多种肿瘤细胞的研究也证实，IGF‐ⅠR在许多肿瘤细胞表面都上调表达，这使得各种靶向IGF‐ⅠR的单克隆抗体不断得到研发，且其中一些已经进入临床研究阶段。此文就IGF‐ⅠR结构、IGF‐ⅠR在肿瘤发生发展中的作用以及靶向IGF‐ⅠR的单克隆抗体的研发和临床应用加以综述。

In recent years ,more and more studies have shown that insulin‐like growth factor‐Ⅰreceptor （IGF‐ⅠR） plays an important role in tumor development and progression ,and the inhibition of IGF‐ⅠR signal pathway would effectively inhibit many kinds of tumor cells proliferation in vivo and vitro . In addition ,the studies of several kinds of tumors confirm that the expression of IGF‐ⅠR is up‐regulated on tumor cell surface ,which drives the development of monoclonal antibodies targeting IGF‐ⅠR .Some monoclonal antibodies have already been tested in a variety of clinical studies .This article discusses the structure of IGF‐ⅠR ,its physiological function in development and progression of tumors ,research and development of monoclonal antibodies targeting IGF‐ⅠR and their therapeutic uses .